You may be eligible to participate in the study.

Share your results and the study information with your doctor.

Age 18 or older

Have a confirmed diagnosis of chronic primary ITP

Have tried at least two ITP therapies that have not worked or stopped working

For your doctor: Description of the Meza ITP study

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Mezagitamab Subcutaneous Injection in Participants with Chronic Primary Immune Thrombocytopenia

clinicaltrials.gov listing: NCT06722235

This website is intended only for residents of the United States.

TAK-079-3002_Meza ITP_Patient Website_V1.0_04 AUGUST2025_US